EMS Magchair gains as clinics outpace home Kegel devices in Russia

By 2026, demand for professional pelvic-floor therapy in Russia is rising faster than sales of home Kegel gadgets, with clinics reporting a 60% annual increase in patient flow. The article argues that clinic-based HIFEM treatment is becoming the preferred option for women who need more than maintenance or prevention.

Why it matters: - The Russian women's health market is splitting into two paths: inexpensive home devices for maintenance and clinic-based therapy for treatment. - The shift matters because clinics offering Deppulse EMS Magchair report stronger demand, while home devices appear to function more as a starting point than a full solution. - The article argues that women with postpartum changes, mild incontinence or pelvic-floor dysfunction are moving toward professional care when home tools do not deliver enough results.

What happened: - By 2026, the flow of patients to clinics offering Deppulse EMS Magchair rose 60% year over year. - The article compares three categories of pelvic-floor devices: biofeedback trainers such as Elvie, Perifit and KegelSmart; TENS/EMS stimulators; and professional HIFEM chairs. - The comparison centers on Deppulse EMS Magchair, described as a 7 Tesla HIFEM chair used in clinic settings.

The details: - Biofeedback trainers work through app-guided voluntary contractions and are said to engage about 30% to 40% of muscle fibers. - TENS/EMS devices use surface electrical current to a depth of 2 to 3 cm and are said to engage about 40% to 50% of muscle fibers. - Professional HIFEM chairs use focused magnetic fields that reach up to 10 cm and are said to engage up to 100% of muscle fibers. - The article says home trainers create force equal to 10% to 15% of maximal voluntary contraction, and incorrect technique can reduce the effect to near zero. - The article says surface electrical stimulation can cause discomfort and pain, which may lead users to lower intensity and reduce stimulation depth. - EMS Magchair is described as producing supramaximal contractions that exceed voluntary effort by 4 to 5 times. - A 30-minute session is said to generate more than 12,000 contractions, including deep muscles such as the levator ani. - For mild dysfunction and prevention, the article recommends home exercises combined with biofeedback. - For moderate dysfunction, including postpartum muscle stretching or mild incontinence, the article recommends a course of 6 to 10 EMS Magchair sessions. - For severe dysfunction, including stage I-II prolapse and pronounced incontinence, the article says only professional therapy is appropriate. - A home device is priced at 8,000 to 15,000 rubles and typically ends the customer relationship after purchase. - A clinic course of 8 sessions costs 24,000 to 36,000 rubles, or 3,000 to 4,500 rubles per session. - Repeat preventive courses may be done every 6 to 12 months. - The article estimates a clinic can recoup a device costing about 1.2 million rubles in 3 to 4 months with five patients per day.

Between the lines: - The piece frames home devices as demand creators and clinics as the place where that demand converts into revenue. - It also frames HIFEM as the next clinical step for patients who want treatment rather than routine muscle training. - The economic argument is as important as the medical one: clinic protocols create recurring visits, while home devices usually do not.

What's next: - Clinics are likely to keep promoting HIFEM as a higher-intensity option for postpartum recovery, incontinence and pelvic-floor dysfunction. - The article suggests some patients will keep using home exercises alongside clinic treatment, but only under physician guidance. - It also warns that combining home electrostimulation with chair-based therapy should be coordinated with a gynecologist, including avoiding home stimulators 48 hours before a chair session.

The bottom line: - In this market framing, home Kegel devices handle prevention and habits, while EMS Magchair is positioned as the clinic-grade solution for deeper dysfunction and stronger commercial returns.